FMP
Inhibrx Biosciences, Inc.
INBX
NASDAQ
Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates includes INBRX-109, a tetravalent therapeutic candidate targeting death-receptor 5 that is in phase 2 clinical trial for the treatment of unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 that is in phase 2 clinical trial for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head and neck cancer, gastric (GIST) and gastroesophageal adenocarcinoma (GEA) cancer, renal cell carcinoma, and urothelial (transitional) cell carcinoma. The company was incorporated in 2024 and is based in La Jolla, California.
14.1 USD
-0.05 (-0.355%)
INBX Financial Statements
Year
2023
2022
2021
2020
CF from Operating Activities
-193.31M
-115.3M
-80.32M
-47.97M
Net Income
-239.73M
-145.23M
-81.77M
-76.12M
Depreciation & Amortization
1.19M
1.23M
1.2M
1.02M
Deferred Income Taxes
0
0
-9k
-2.14M
Stock Based Compensation
24.85M
17.79M
15.05M
5.02M
Change in Working Capital
15.35M
3.16M
-17.52M
12.69M
Accounts Receivable
-521k
130k
-167k
117k
Inventory
0
0
-11.03M
7.76M
Accounts Payable
2.11M
-705k
-4.64M
10.43M
Other Working Capital
13.76M
3.74M
-1.67M
-5.61M
Other Non-Cash Items
5.03M
5.09M
2.73M
11.56M
CF from Investing Activities
-4.59M
-686k
-809k
-1.36M
Investments in Property, Plant & Equipment
-4.59M
-686k
-864k
-1.36M
Net Acquisitions
0
0
55k
0
Investment Purchases
0
0
0
0
Sales/Maturities of Investments
0
0
0
0
Other Investing Activites
0
0
55k
0
CF from Financing Activities
201.96M
258.55M
83.77M
166.46M
Debt Repayment
0
-128.81M
-39.99M
-5.46M
Common Stock Issued
201.96M
127.37M
40.2M
136.85M
Common Stock Repurchased
0
0
0
0
Dividends Paid
0
0
0
0
Other Financing Activites
201.96M
128.81M
83.77M
166.46M
Free Cash Flow
-197.9M
-115.99M
-81.19M
-49.33M
Operating Cash Flow
-193.31M
-115.3M
-80.32M
-47.97M
Capital Expenditures
-4.59M
-686k
-864k
-1.36M
Cash at Beginning of Period
273.87M
131.3M
128.66M
11.54M
Cash at End of Period
277.92M
273.87M
131.3M
128.66M
Net Change In Cash
4.06M
142.56M
2.64M
117.12M
Retained Earning Schedule
Year
2023
2022
2021
2020
Retained Earnings (Previous Year)
-372.37M
-227.15M
-145.38M
-69.25M
Net Income
-241.36M
-145.23M
-81.77M
-75.64M
Stock Repurchases
0
0
0
0
Dividend Paid
0
0
0
0
Retained Earnings
-613.73M
-372.37M
-227.15M
-145.38M
Other Distributions
-241.36M
-145.23M
-81.77M
-76.12M
PPE Schedule
Year
2023
2022
2021
2020
Gross PPE
9.37M
7.22M
9.49M
11.32M
Annual Depreciation
1.19M
1.23M
2.69M
2.39M
Capital Expenditure
-4.59M
-686k
-864k
-1.36M
Net PPE
12.77M
6.68M
7.67M
10.29M
Intangible and Goodwill Schedule
Year
2023
2022
2021
2020
Acquisitions and Adjustments
0
0
0
0
Goodwill (Previous Year)
0
0
0
0
Goodwill
0
0
0
0
All figures are in USD.
